StarkAge Therapeutics is a privately-held biotechnology start-up, whose ambition is to delay or halt disease progression and improve quality of life of patients with age-related diseases, associated with senescent cells accumulation. It builds on its unique disease-specific exosomal / EV technology while harnessing immunotherapy approach, to address very large senescence unmet medical needs.